ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Teva continues portfolio divestment

by Rick Mullin
June 27, 2016 | APPEARED IN VOLUME 94, ISSUE 26

Teva Pharmaceutical Industries continues to divest products to satisfy antitrust regulators assessing its planned acquisition of Allergan’s generic drug business. Impax Laboratories will pay $586 million for 15 marketed generics plus the rights to products not yet launched and to the pending Abbreviated New Drug Application (ANDA) for the generic equivalent of Concerta, a product on which the two companies collaborated. Sagent Pharmaceuticals, meanwhile, will pay $40 million for five ANDAs pending in the U.S. Earlier this month, Teva sold a raft of ANDAs to Dr. Reddy’s Laboratories.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment